Fully enrolled the second dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); enrollment ... and vascular endothelial growth factor A (VEGF-A) signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback